JPWO2021160881A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021160881A5
JPWO2021160881A5 JP2022548838A JP2022548838A JPWO2021160881A5 JP WO2021160881 A5 JPWO2021160881 A5 JP WO2021160881A5 JP 2022548838 A JP2022548838 A JP 2022548838A JP 2022548838 A JP2022548838 A JP 2022548838A JP WO2021160881 A5 JPWO2021160881 A5 JP WO2021160881A5
Authority
JP
Japan
Prior art keywords
combination according
antigen
mrna molecules
combination
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548838A
Other languages
Japanese (ja)
Other versions
JP2023518340A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/053633 external-priority patent/WO2021160881A1/en
Publication of JP2023518340A publication Critical patent/JP2023518340A/en
Publication of JPWO2021160881A5 publication Critical patent/JPWO2021160881A5/ja
Pending legal-status Critical Current

Links

Claims (13)

組合せであって、
－CD40L、構成的に活性型のTCR4（caTLR4）、及びCD70を含むリストから選択される機能性免疫賦活タンパク質をコードする1つ以上のmRNA分子と、
－細菌、ウイルス、又は真菌の抗原をコードする1つ以上のmRNA分子と、
を含み、前記組合せが、鼻腔内製剤の形態である、組合せ。 A combination,
- one or more mRNA molecules encoding a functional immunostimulatory protein selected from the list including CD40L, constitutively active TCR4 (caTLR4), and CD70;
- one or more mRNA molecules encoding bacterial, viral or fungal antigens;
wherein said combination is in the form of an intranasal formulation. 前記1つ以上のmRNA分子が、前記機能性免疫賦活タンパク質CD40L、caTLR4及びCD70の全てをコードする、請求項1に記載の組合せ。 2. The combination according to claim 1, wherein said one or more mRNA molecules encode all of said functional immunostimulatory proteins CD40L, caTLR4 and CD70. 前記抗原が気道病原体由来の抗原である、請求項1又は2に記載の組合せ。 3. The combination according to claim 1 or 2, wherein the antigen is an antigen derived from a respiratory tract pathogen. 前記抗原が、M（マトリックス）、N（ヌクレオカプシド）若しくはS（スパイク）抗原、T細胞刺激エピトープを含み、T調節性エピトープを抑制するように設計された人工抗原、又は抗体応答を誘導するように設計された表面抗原である、請求項1～3のいずれか一項に記載の組合せ。 The antigen may be an M (matrix), N (nucleocapsid) or S (spike) antigen, an artificial antigen that includes a T cell stimulating epitope and is designed to suppress a T regulatory epitope, or to induce an antibody response. The combination according to any one of claims 1 to 3, which is an engineered surface antigen. 前記気道病原体がコロナウイルスである、請求項3に記載の組合せ。 4. The combination according to claim 3, wherein the respiratory tract pathogen is a coronavirus. 前記mRNA分子が、脂質ベースのナノ粒子等のナノ粒子の形態で製剤化される、請求項1～5のいずれか一項に記載の組合せ。 A combination according to any one of claims 1 to 5, wherein the mRNA molecule is formulated in the form of nanoparticles, such as lipid-based nanoparticles. 前記mRNA分子が、リポプレックス、デンドリマー、ポリプレックス又はハイブリッドリポポリプレックスの形態で製剤化される、請求項1～5のいずれか一項に記載の組合せ。 Combination according to any one of claims 1 to 5, wherein the mRNA molecules are formulated in the form of lipoplexes, dendrimers, polyplexes or hybrid lipopolyplexes. 前記mRNA分子が、ポリエチレンイミンを使用してポリプレックスの形態で製剤化される、請求項7に記載の組合せ。 8. A combination according to claim 7, wherein the mRNA molecule is formulated in the form of a polyplex using polyethyleneimine. 1つ以上の前記mRNA分子が5'CAP-1構造を含む、請求項1～8のいずれか一項に記載の組合せ。 A combination according to any one of claims 1 to 8, wherein one or more of the mRNA molecules comprises a 5'CAP-1 structure. 1つ以上の前記mRNA分子が、1つ以上の修飾ヌクレオシド、特にN1-メチル-シュードウリジンを含む、請求項1～9のいずれか一項に記載の組合せ。 A combination according to any one of claims 1 to 9, wherein one or more of the mRNA molecules comprises one or more modified nucleosides, in particular N1-methyl-pseudouridine. ヒト医学又は獣医学において使用される、請求項1～10のいずれか一項に記載の組合せ。 Combination according to any one of claims 1 to 10 for use in human or veterinary medicine. 感染性疾患の予防及び／又は治療に使用される、請求項1～10のいずれか一項に記載の組合せ。 The combination according to any one of claims 1 to 10, for use in the prevention and/or treatment of infectious diseases. 請求項1～10のいずれか一項に記載の組合せを含む感染性疾患の予防又は治療剤であって、予防又は治療を必要とする被験体に投与する、予防又は治療剤。 A prophylactic or therapeutic agent for infectious diseases comprising the combination according to any one of claims 1 to 10 , which is administered to a subject in need of prevention or treatment.
JP2022548838A 2020-02-14 2021-02-15 intranasal mRNA vaccine Pending JP2023518340A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20157300.3 2020-02-14
EP20157300 2020-02-14
PCT/EP2021/053633 WO2021160881A1 (en) 2020-02-14 2021-02-15 Intranasal mrna vaccines

Publications (2)

Publication Number Publication Date
JP2023518340A JP2023518340A (en) 2023-05-01
JPWO2021160881A5 true JPWO2021160881A5 (en) 2024-01-25

Family

ID=69593570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548838A Pending JP2023518340A (en) 2020-02-14 2021-02-15 intranasal mRNA vaccine

Country Status (13)

Country Link
US (1) US20230071518A1 (en)
EP (1) EP4103226A1 (en)
JP (1) JP2023518340A (en)
KR (1) KR20230004447A (en)
CN (1) CN115443148A (en)
AU (1) AU2021219304A1 (en)
BR (1) BR112022015666A2 (en)
CA (1) CA3170239A1 (en)
IL (1) IL295507A (en)
MX (1) MX2022009943A (en)
TW (1) TW202144002A (en)
WO (1) WO2021160881A1 (en)
ZA (1) ZA202209779B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
KR20230164648A (en) 2020-12-22 2023-12-04 큐어백 에스이 RNA vaccines against SARS-CoV-2 variants
WO2023037320A1 (en) * 2021-09-10 2023-03-16 Intron Biotechnology, Inc. Mucosal messenger rna vaccine
WO2023108076A1 (en) * 2021-12-08 2023-06-15 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
EA035313B1 (en) * 2013-11-12 2020-05-27 Врейе Университейт Брюссель Rna transcription vector and uses thereof
BR112016024644A2 (en) * 2014-04-23 2017-10-10 Modernatx Inc nucleic acid vaccines
AU2017350488B2 (en) * 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines

Similar Documents

Publication Publication Date Title
Akbari et al. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia
Hess et al. Phage display as a tool for vaccine and immunotherapy development
US20220202934A1 (en) Respiratory virus nucleic acid vaccines
TWI624280B (en) Nasal influenza vaccine composition
JP2010516290A5 (en)
ES2576036T3 (en) Vaccination Methods
AU2014212104B2 (en) Immunogenic compositions comprising silicified virus and methods of use
WO2014063601A1 (en) Vaccine for inducing specific immunity of tumor and application thereof
Lin et al. Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice
JPWO2021160881A5 (en)
Witeof et al. Atomic-Layer Deposition Processes Applied to Phage λ and a Phage-like Particle Platform Yield Thermostable, Single-Shot Vaccines
Damodharan et al. A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2
JP4846598B2 (en) Mono-nonspecific immunity inducer based on attenuated rabbit myxoma virus
Shah et al. A review on modern use of intranasal vaccination in the treatment of SARS-COV-2
Lutz et al. Advanced nanobiomedical approaches to combat coronavirus disease of 2019
CN116785423A (en) mRNA vaccine for fusion expression of monkey pox virus protective antigen, composition for delivering mRNA vaccine, preparation method and application thereof
Khawaja et al. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation
JP2007534664A5 (en)
JP2023012539A (en) Nasal hepatitis B vaccine composition and method for producing the same
Robertson et al. International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety
CN113185586B (en) T cell epitope polypeptide derived from SARS-CoV-2 coding protein and application thereof
JP7397079B2 (en) Application of transferrin, transferrin receptors and their antibodies in the preparation of SARS-CoV-2 virus drugs
Shah et al. A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems. Vaccines 2021, 9, 1086
Zhai et al. Dongmei Yu. Knowledge Distillation for COVID-19 Therapeutics
Nátz et al. Rational design of formulated DNA vaccines: the DermaVir approach